The Kalluri laboratory recently acquired a NanoFCM system to characterize exosomes size, concentration, and biochemical properties. Given the difficulties with single exosomes phenotyping, NanoFCM provides a versatile platform for accurate and reproducible results. The Flow NanoAnalyzer gives insights not possible with other single particle detection methods. Precise particle size, particle concentration and biochemical property evaluation are essential to his project. We look forward to great research from Prof. Kalluri’s Group.
For more than 75 years, MD Anderson has been a global leader in the fight to end cancer. MD Anderson has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey. MD Anderson ranks first in the number and amount of research grants awarded by the National Cancer Institute.